Subtype
Castration-Resistant Prostate Carcinoma
CI-CAN-00007376CRPCExplore in graph →
221 active trials12 approved drugs15 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007376CRPCExplore in graph →
Variants & evidence
26 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|
| ATM Mutation3 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID8505This study (PMID 32343890) by de Bono et al, is a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) w… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| Rucaparib | Predictive | B | Does Not Support Sensitivity Response | 4 | accepted | EID13268In the exploratory ATM subgroup of the randomized phase III TRITON3 trial, 103 patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious ATM alterations w… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| Enzalutamide + TalazoparibCombination | Predictive | B | Does Not Support Sensitivity Response | 1 | submitted | EID11736This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC) PMID 38049622 · Fizazi et al., 2024 · Open in CIViC | civic |
| ATR Loss-of-function1 | |||||||
| Enzalutamide + TalazoparibCombination | Predictive | A | Supports Sensitivity Response | 2 | submitted | EID12217In the phase 3 TALAPRO-2 trial 805 patients with castration-resistant prostate cancer were enrolled and randomized to talazoparib or placebo plus enzalutamide treatment. Patients were tested for homol… (full text at CIViC) PMID 37285865 · Agarwal et al., 2023 · Open in CIViC | civic |
| BARD1 Mutation1 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11209This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| BRCA1 Mutation3 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11203This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| Rucaparib | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID13266In a prespecified subgroup analysis of the randomized phase III TRITON3 trial, patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious BRCA1 alterations… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| Enzalutamide + TalazoparibCombination | Predictive | A | Supports Sensitivity Response | 2 | submitted | ||
| BRCA1 Mutation + BRCA2 MutationBRCA2BRCA12 | |||||||
| Abiraterone + NiraparibCombination | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11738A phase 3 trial (NCT03748641) evaluated the clinical benefit of the PARP inhibitor niraparib in combination with abiraterone acetate plus prednisone (AAP) in metastatic castration-resistant prostate … (full text at CIViC) PMID 36952634 · Chi et al., 2023 · Open in CIViC | civic |
| Rucaparib | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID12944In the BRCA-altered cohort (n = 302; deleterious BRCA1/2 alterations) of the global, randomized, open-label phase III TRITON3 trial (NCT02975934) in mCRPC, pts treated with rucaparib (600 mg twice/day… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| BRCA2 Mutation3 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID8842In phase 3 trial of 387 patients comparing olaparib and new hormonal agent (enzalutamide or abiraterone) therapy for patients with metastatic castration-resistant prostate cancer harboring homologous … (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| Rucaparib | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID13267In a prespecified subgroup analysis of the randomized phase III TRITON3 trial, patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious BRCA2 alterations… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| Enzalutamide + TalazoparibCombination | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11733 | |
| BRIP1 Mutation1 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11208This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| CDK12 Mutation2 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11204This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| Enzalutamide + TalazoparibCombination | Predictive | A | Supports Sensitivity Response | 1 | submitted | EID11735This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC) PMID 38049622 · Fizazi et al., 2024 · Open in CIViC | civic |
| CHEK1 Mutation1 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11210This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| CHEK2 mutation2 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID11205This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| Enzalutamide + TalazoparibCombination | Predictive | B | Does Not Support Sensitivity Response | 1 | submitted | EID11737This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC) PMID 38049622 · Fizazi et al., 2024 · Open in CIViC | civic |
| FANCL Mutation1 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 1 | submitted | EID11211This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| PALB2 Mutation1 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID8504This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| PPP2R2A Mutation1 | |||||||
| Olaparib | Predictive | B | Does Not Support Sensitivity Response | 2 | accepted | EID11206This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| RAD51B Mutation1 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11212This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| RAD51C Mutation1 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 1 | submitted | EID11213This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| RAD51D Mutation1 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 2 | accepted | EID11214This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
| RAD54L Mutation1 | |||||||
| Olaparib | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID11207This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC) PMID 32343890 · de Bono et al., 2020 · Open in CIViC | civic |
Data updated 23 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC)
PMID 38049622 · Fizazi et al., 2024 · Open in CIViC
| civic |
This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC)
PMID 38049622 · Fizazi et al., 2024 · Open in CIViC
| civic |